Genezen's New Chapter with Mike Wourms as COO
Genezen, regarded as a top gene therapy contract development and manufacturing organization (CDMO), has recently made an exciting leadership move by appointing Mike Wourms as its Chief Operations Officer. This strategic appointment comes at a pivotal moment, reflecting the organization’s ambitions to expand its footprint in the rapidly evolving gene therapy landscape.
Strengthening Genezen's Leadership Team
With over ten years of experience in gene therapy and a robust background in manufacturing, Mike Wourms is perfectly aligned with Genezen's mission. His impressive career trajectory includes roles in reputable companies that paved the way for his expertise in viral vector manufacturing.
Experience That Matters
Before joining Genezen, Mike held the position of COO at Arranta Bio and has worked with other prestigious organizations like Elevate Bio and Brammer Bio. His specialized knowledge in Adeno-Associated Viral (AAV) and Lentiviral Vector (LVV) manufacturing is invaluable as Genezen continues to enhance its capabilities.
A Vision for Growth
Genezen is currently experiencing significant growth momentum, particularly after acquiring a new 86,000 square foot facility. This site is equipped with state-of-the-art technology, enabling Genezen to partner effectively with innovator companies. The goal is to develop and manufacture gene and cell therapies that not only reach the marketplace but effectively address clinical needs on a global scale.
The Importance of Collaboration
Mike Wourms expressed his enthusiasm upon joining Genezen, emphasizing the collaborative spirit of the team. His commitment to delivering top-notch support to Genezen’s partners aligns with the organization's mission to bring transformative therapies to market. His words resonate with the determination to drive advancements in cell and gene therapies through scientifically-grounded development and manufacturing solutions.
Support from Leadership
Steve Favaloro, Chairman and CEO of Genezen, echoed excitement regarding Mike's joining the team. His proven track record in fostering partnerships with therapeutic innovators is expected to significantly enhance Genezen’s ability to bring cutting-edge treatments from development into clinical settings.
About Genezen
Genezen stands out as a rapidly growing CDMO with extensive experience in viral vector manufacturing. With the flexibility to navigate various stages of development and delivery, Genezen serves a diverse clientele, including academic institutions and large multinational pharmaceutical companies. By maintaining a customer-centric approach, Genezen tailors its services to meet the unique needs of its partners, ensuring effective delivery of life-saving gene and cell therapies.
For media inquiries, Genezen remains accessible through prominent team members, enhancing transparency and communication within the industry.
Frequently Asked Questions
What role has Mike Wourms been appointed to at Genezen?
Mike Wourms has been appointed as the Chief Operations Officer at Genezen, bringing extensive experience in gene therapy manufacturing.
What does Genezen specialize in?
Genezen specializes in gene therapy contract development and manufacturing, focusing on delivering life-saving gene and cell therapies.
How does Genezen support its partners?
Genezen supports its partners by tailoring its services to various sizes and stages, ensuring effective collaboration throughout the development process.
What are Genezen's capabilities?
Genezen possesses state-of-the-art facilities for viral vector manufacturing and offers comprehensive solutions from concept to commercial delivery.
Why is this appointment significant for Genezen?
This appointment strengthens Genezen's leadership team, essential for navigating the rapid growth and development of innovative therapies.
